CELC stock forecast, quote, news & analysis

Key Takeaways

• Celcuity (CELC) shares declined approximately 17.8% over the last 30 days, falling from $99.95 on June 26 to $82.19 as of July 27, 2026.
• The FDA approved the company's first commercial product, Revtorpyk (gedatolisib), on July 14 — but a delayed commercial launch timeline to late Q3 2026 triggered a sharp 17.6% single-day sell-off.
• A large shareholder, Baker Bros. Advisors LP, sold approximately 2.84 million shares on July 14, amplifying downward pressure.
• Over the last quarter, CELC lost approximately 34.6% as a combination of disappointing Phase 3 data, a $500 million convertible note offering, and Russell index removals weighed on the stock.
• Despite the sell-off, Wall Street analysts maintain a predominantly bullish consensus, with price targets ranging from $147 to $178.
• A securities law firm announced an investigation into potential claims against the company on July 20, adding to investor uncertainty.

Celcuity Inc. (CELC) Company Overview and Market Position

Celcuity Inc. is a biotechnology company focused on developing targeted therapies for solid tumors. Headquartered in Minneapolis, Minnesota, the company recently transitioned from a clinical-stage to a commercial-stage enterprise following the FDA approval of Revtorpyk (gedatolisib), a first-in-class therapy that comprehensively inhibits the PI3K/AKT/mTOR (PAM) pathway — a key signaling route driving cancer cell growth and survival. Revtorpyk is the first drug to inhibit all class I PI3K isoforms and both mTOR complexes simultaneously. The company estimates the addressable U.S. market at over $6 billion for HR-positive/HER2-negative advanced breast cancer patients receiving second-line therapy. Celcuity is also pursuing label expansions into PIK3CA-mutant breast cancer and first-line settings, as well as metastatic castration-resistant prostate cancer.

Celcuity Inc. (CELC) Stock Price Performance: Last 30 Days vs. Quarter

Over the past 30 days, CELC stock declined from a closing price of $99.95 on June 26, 2026, to an intraday level of $82.19 on July 27, 2026 — a drop of approximately 17.8%. The decline was not linear: the stock rallied strongly in early July, surging as high as $115.72 on July 7, before collapsing after the July 14 FDA approval announcement. Zooming out to the quarterly view, the picture is starker. From a close of $125.68 on April 27, 2026, CELC has fallen roughly 34.6%, reflecting a multi-month downtrend driven by clinical data disappointments, financing dilution, index deletions, and now commercial launch uncertainty.

What Drove CELC Stock Price in the Last 30 Days

The dominant catalyst over the past 30 days was the FDA's July 14 approval of Revtorpyk for adults with HR-positive, HER2-negative, PIK3CA wild-type, locally advanced or metastatic breast cancer. While the approval itself was widely anticipated, Celcuity disclosed that the commercial launch would occur in "late Q3 2026" rather than sooner — a timeline analysts at Stifel and Leerink Partners described as extended relative to prior management commentary on launch readiness. The stock plummeted 17.6% to $91.51 on July 15 in response. Compounding the sell-off, Baker Bros. Advisors LP, a major institutional holder, sold 2.84 million shares on the same day. Additionally, the FDA-approved label revealed higher-than-expected treatment discontinuation rates in clinical testing, raising concerns about real-world tolerability. On July 20, the law firm Kirby McInerney LLP announced an investigation into whether Celcuity may have violated federal securities laws, further unsettling investors. Earlier in the period, the stock also absorbed the impact of Celcuity's removal from multiple Russell indices on June 27, which reduced passive fund ownership and trading liquidity.

What Drove CELC Stock Performance Over the Last Quarter

The quarterly decline originated in early June, when Celcuity presented detailed Phase 3 VIKTORIA-1 trial results at the American Society of Clinical Oncology annual meeting. Although the trial met its primary endpoint — demonstrating that Revtorpyk-based regimens cut the risk of disease progression or death by roughly 50% compared to Novartis' NVS Piqray plus fulvestrant — the median progression-free survival of 11.1 months came in below the 11.6 months reported in earlier Phase 1b data. The presentation also disclosed a Grade 5 treatment-related adverse event linked to Pfizer's PFE Ibrance (palbociclib), which triggered a 21% single-day drop on June 2. Days later, Celcuity announced and priced a $500 million convertible senior notes offering due 2032, raising dilution and debt concerns. Wells Fargo subsequently lowered its price target from $183 to $166, though it maintained an Overweight rating. By late June, the removal from Russell indices erased another pillar of institutional support, leaving the stock vulnerable heading into the July FDA decision.

Trending AI Robots

In volatile markets like biotechnology, where binary events such as FDA decisions can dramatically swing stock prices, traders increasingly turn to AI-driven tools for data-backed guidance. Tickeron's Trending AI Robots page curates a selection of top-performing AI trading bots from a pool of hundreds that actively trade thousands of tickers across diverse strategies and timeframes. Only the most relevant and consistently strong-performing bots are featured in this curated section, giving traders a streamlined view of strategies currently generating results. Bots vary by risk profile, holding period, and methodology — from short-term momentum plays to longer-term trend-following approaches — allowing users to explore AI-driven trading alongside their own research.

CELC Stock Forecast Drivers: What Investors Should Watch Next

The most immediate factor for CELC is the execution of Revtorpyk's commercial launch in late Q3 2026. Investors will scrutinize early prescription trends, payer coverage decisions, and the company's ability to build physician awareness. Also critical is Celcuity's planned regulatory submission in Q3 2026 for a label expansion into PIK3CA-mutant patients, supported by the VIKTORIA-1 mutant cohort data. Further ahead, the ongoing Phase 3 VIKTORIA-2 study in the first-line setting and the evaluation of Revtorpyk in metastatic castration-resistant prostate cancer represent the next major pipeline catalysts. Risks include slower-than-expected commercial uptake, the company's heavy cash burn and debt load following the $500 million convertible offering, competitive threats from established PI3K inhibitors, and the outcome of the securities investigation. While analyst price targets remain elevated — ranging from $147 at Leerink Partners to $178 at Craig-Hallum — the stock's near-term trajectory will likely hinge on tangible launch metrics and regulatory progress.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.